Tyrosine News and Research

RSS

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Chronic myelogenous leukemia patient survey shows that side effects are a serious issue

Startling findings from a new CML (chronic myelogenous leukemia) patient survey were presented at a satellite meeting of the American Society of Hematology annual meeting, in San Francisco.

8 Dec 2008

New chemotherapy pill shows promise for stubborn lymphomas

A new chemotherapy pill is showing early success in treating people with stubborn lymphomas, according to scientists at the University of Rochester Medical Center. Doctors reported that the drug is halting disease in nearly half of the patients with chronic lymphocytic leukemia, and in patients with more aggressive lymphoma as well.

8 Dec 2008

Genaera starts trial of Trodusquemine in overweight and obese type 2 diabetes

Genaera Corporation has announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics.

1 Dec 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice.

18 Nov 2008

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco.

18 Nov 2008

Alteration of a gene causes neuroblastoma

Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.

7 Nov 2008

Scientists sequence genome of a cancer patient

For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.

6 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Gene study sheds new light on lung cancer

A multi-institution team, funded by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), today reported results of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma. The findings should help pave the way for more individualized approaches for detecting and treating the nation's leading cause of cancer deaths.

22 Oct 2008

Getting to grips with the complexity of disease proteins

Drug molecules seldom act simply on one protein but on protein complexes and networks. A deeper understanding of these 'cooperative assemblies' should lead to better targeting of drugs.

20 Oct 2008

Significant benefits in non-small-cell lung cancer from customizing erlotinib treatment

Lung cancer patients whose tumors carry specific genetic mutations can achieve significantly longer survival when treated with targeted therapies such as erlotinib, Spanish researchers report.

15 Sep 2008

Antisoma commences phase II trial of AS1411 in metastatic renal cell carcinoma

Cancer drug developer Antisoma plc today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).

4 Sep 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Australian researchers reveal how cancers become more aggressive

A team of Australian scientists have discovered how some cancers are able to mutate into more aggressive and potentially fatal cancers in the human body.

11 Aug 2008

Cancer survival secrets discovered by Australian researchers

A team of Monash University researchers has uncovered the role of a family of enzymes in the mutation of benign or less aggressive tumours into more aggressive, potentially fatal, cancers in the human body.

11 Aug 2008

Researcher develops method for early detection of leukemia relapse

Researchers at the Fred Hutchinson Cancer Research Center have developed a method that allows for the early detection of a common mechanism of resistance on drug treatment for chronic myeloid leukemia.

10 Jul 2008

Circulating tumor cells can reveal genetic signature of dangerous lung cancers

Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream.

9 Jul 2008